GastroIntestinal Diseases

DOR BioPharma Announces Named Patient Access Program for orBec(R) in Singapore and Malaysia in Collaboration With Steward Cross Pte Ltd

The Earth Times Online Newspaper (Free subscription) | 07/18/2008

EWING, NJ -- 07/18/08 -- DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and v..

DOR BioPharma, Inc.: DOR BioPharma Announces Named Patient Access Program for orBec(R) in Singapore and Malaysia in Collaboration With Steward Cross Pte Ltd

Market Wire - Medical and Healthcare: Healthcare (Free subscription) | 07/18/2008

EWING, NJ (MARKET WIRE) DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that it has entered into a collaboration with Steward Cross Pte Ltd (Steward Cross), a specialty...

New Research From Rhode Island Hospital May Help Predict Outcomes For Stomach Cancer Patients

Medical News Today (Free subscription) | 07/18/2008

Researchers at Rhode Island Hospital have identified two potential molecular markers that may predict outcomes for patients with stomach cancer, one of the most common and fatal cancers worldwide. According to the study, published in Clinical Cancer Research, patients who had poor outcomes following surgery for stomach cancer also had extremely low amounts of two proteins, known as gastrokine 1 and...

Virulence Factor That Induces Fatal Fungal Infection Identified By Singapore Scientists

Medical News Today (Free subscription) | 07/18/2008

Scientists here have found that certain substances from bacteria living in the human intestine cause the normally harmless Candida albicans fungus to become highly infectious. This discovery by researchers at Singapore's Agency for Science, Technology and Research (A*STAR)'s Institute of Molecular and Cell Biology (IMCB) could possibly lead to the development of novel treatments for immunocompromised...

• Virulence Factor That Induces Fatal Candida Infection Identified - Science Daily
• Virulence factor that induces fatal Candida infection identified - Eurekalert

Stomach Virus Detection Protein Discovered

Medical News Today (Free subscription) | 07/18/2008

A innate immune sensor has been discovered that detects the presence of stomach viruses in the body. This protein, named MDA-5, triggers an immune response, and might give scientists information to develop a treatment to prevent or reduce infections of this kind, according to an article released on July 18, 2008 in the open access journal PLoS Pathogens.

DOR BioPharma, Inc.: DOR BioPharma Enters Into Collaborative Agreement With IDIS for Named Patient Access of orBec(R) in Europe

Market Wire - Government: International (Free subscription) | 07/15/2008

EWING, NJ (MARKET WIRE) DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious gastrointestinal diseases and vaccines against certain bioterrorism agents, announced today that it has executed a definitive collaborative agreement with IDIS Limited ("IDIS"), for the...

Mundipharma Submits New Analgesic Targin(R) (Prolonged Release Oxycodone / Naloxone Combination) For European Approval

Medical News Today (Free subscription) | 07/10/2008

Mundipharma announced that Targin®, an oral prolonged-release oxycodone / naloxone combination tablet, has been submitted for regulatory approval in Europe. Targin® is a combination of a strong opioid receptor agonist, oxycodone, and a locally acting opioid receptor antagonist, naloxone.

Internet Search

Thinking made Easy (Free subscription) | 07/08/2008

Introduction Crohn’s disease is actually a continuous disorder which causes inflammation of the digestive or the gastrointestinal tract which can affect any area of the said tract, from the mouth to the anus, but usually affects the lower part of the small intestine called the ileum. The said disease is...

Adolor Provides Update On Entereg® (alvimopan) OBD Program - FDA Lifts Clinical Hold On OBD IND

Medical News Today (Free subscription) | 07/07/2008

Adolor Corporation (Nasdaq: ADLR) today issued an update on the Entereg® (alvimopan) Program for chronic opioid bowel dysfunction (OBD), under development in collaboration with GlaxoSmithKline (NYSE: GSK). The U. S. Food and Drug Administration (FDA) has concluded that clinical investigations relating to alvimopan in OBD may now proceed, and has therefore lifted the clinical hold on the OBD Investigational...

European Medicines Agency Approves Relistor™ The First-In-Class Treatment Of Opioid-Induced Constipation (Oic) In Advanced-Illness Patients

Medical News Today (Free subscription) | 07/04/2008

Wyeth Pharmaceuticals, 3rd July, announced that it has received EMEA marketing approval for Relistor™ (methylnaltrexone bromide) subcutaneous injection. This first-in-class treatment is indicated for opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to the usual laxative therapy has not been sufficient.

Complexity of Crohn's disease revealed

Curing Death by Curing Aging (Free subscription) | 07/01/2008

New research has trebled the number of genetic regions known to be implicated in Crohn's disease, a form of inflammatory bowel disease, to over 30

DOR BioPharma, Inc.: DOR BioPharma Announces Collaboration With Numoda Corporation for the Execution of Confirmatory, Phase 3 Clinical Trial of orBec(R)

Market Wire (Free subscription) | 06/30/2008

EWING, NJ (MARKET WIRE) DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that it has entered into a collaboration with Numoda Corporation (Numoda), experts in rapid information...

Complexity of Crohn's disease revealed as 'gene' count tops 30

Physorg (Free subscription) | 06/29/2008

New research has trebled the number of genetic regions known to be implicated in Crohn's disease, a form of inflammatory bowel disease, to over thirty. The research, published today in the journal Nature Genetics, has identified a number of potential new targets for drug development as well as providing surprising new links between the condition and other common diseases including asthma.

Leading Colorectal Patient Organisation Calls On EU Countries To Improve Poor Standards Of Care

Medical News Today (Free subscription) | 06/26/2008

europacolon has called on all governments to implement existing EU recommendations on colorectal cancer screening following a new report published that shows the disease to be significantly neglected despite being the second most common cancer in Europe.1Welcoming the findings of the report by the London School of Economics,2 Jola Gore-Booth, Director of europacolon said: "For too long colorectal cancer...

First Comprehensive Report On Colorectal Cancer (CRC) Care In Europe And Australia Reveals Urgent Need For Action

Medical News Today (Free subscription) | 06/26/2008

The first cross-country report on the management and funding of colorectal cancer (CRC) reveals an urgent need for action to improve the survival of patients diagnosed with this common cancer in Europe and Australia. Key findings from the report published by the London School of Economics (LSE) confirm that few countries have prioritized CRC screening and treatment.